Established and new rotavirus vaccines: a comprehensive review for healthcare professionals

References

• Chen S-C, Tan L-B, Huang L-M, Chen K-T. Rotavirus infection and the current status of rotavirus vaccines. Journal of the Formosan Medical Association. 2012;111(4):183–17. doi:10.1016/j.jfma.2011.09.024.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rotavirus vaccines - WHO position paper – january 2013. Wkly Epidemiol Rec. 2013;88(5):49–64. doi:10.1016/j.jfma.2011.09.024.
   PubMedGoogle Scholar
• Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagbom M. Rotavirus infection. Nat Rev Dis Primers. 2017;3:17083. doi:10.1038/nrdp.2017.83.
   PubMed Web of Science ®Google Scholar
• Sengupta P. Rotavirus: the challenges ahead. Indian J Community Med. 2009;34(4):279–82. doi:10.4103/0970-0218.58382.
   PubMedGoogle Scholar
• Troeger C, Khalil IA, Rao PC, Cao S, Blacker BF, Ahmed T. Rotavirus vaccination and the global burden of rotavirus diarrhea among children younger than 5 years. JAMA Pediatr. 2018;172(10):958–65. doi:10.1001/jamapediatrics.2018.1960.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Rotavirus vaccines. WHO position paper – december 2009. Wkly Epidemiol Rec. 2009;84(50):533–40. doi:10.1001/jamapediatrics.2018.1960.
   PubMedGoogle Scholar
• Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. World health organization-coordinated global rotavirus surveillance N. Global, regional, and national estimates of rotavirus mortality in children <5 years of age, 2000-2013. Clin Infect Dis. 2016;62(Suppl 2):S96–S105. doi:10.1093/cid/civ1013.
   PubMed Web of Science ®Google Scholar
• Desselberger U. Rotaviruses. Virus Res. 2014;190:75–96. doi:10.1016/j.virusres.2014.06.016.
   PubMed Web of Science ®Google Scholar
• Parashar UD. Rotavirus. Emerg Infect Dis. 1998;4(4):561–70. doi:10.3201/eid0404.980406.
   PubMed Web of Science ®Google Scholar
• Gentsch JR, Laird AR, Bielfelt B, Griffin DD, Banyai K, Ramachandran M. Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. J Infect Dis. 2005;192(Suppl 1):S146–159. doi:10.1086/431499.
   PubMed Web of Science ®Google Scholar
• Desselberger U, Huppertz HI. Immune responses to rotavirus infection and vaccination and associated correlates of protection. J Infect Dis. 2011;203(2):188–95. doi:10.1093/infdis/jiq031.
   PubMed Web of Science ®Google Scholar
• O’Ryan M. Rotarix (RIX4414): an oral human rotavirus vaccine. Expert Rev Vaccines. 2007;6(1):11–19. doi:10.1586/14760584.6.1.11.
   PubMed Web of Science ®Google Scholar
• Tate JE, Patel MM, Steele AD, Gentsch JR, Payne DC, Cortese MM. Global impact of rotavirus vaccines. Expert Rev Vaccines. 2010;9(4):395–407. doi:10.1586/erv.10.17.
   PubMed Web of Science ®Google Scholar
• Yen C, Tate JE, Hyde TB, Cortese MM, Lopman BA, Jiang B. Rotavirus vaccines: current status and future considerations. Hum Vaccin Immunother. 2014;10(6):1436–48. doi:10.4161/hv.28857.
   PubMed Web of Science ®Google Scholar
• Angel J, Franco MA, Greenberg HB. Rotavirus vaccines: recent developments and future considerations. Nat Rev Microbiol. 2007;5(7):529–39. doi:10.1038/nrmicro1692.
   PubMed Web of Science ®Google Scholar
• Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, Glass RI, Estes MK, Pickering LK, Ruiz-Palacios GM. Rotavirus infection in infants as protection against subsequent infections. N Engl J Med. 1996;335(14):1022–28. doi:10.1056/NEJM199610033351404.
   PubMed Web of Science ®Google Scholar
• Dennehy PH. Rotavirus vaccines: an overview. Clin Microbiol Rev. 2008;21(1):198–208. doi:10.1128/CMR.00029-07.
   PubMed Web of Science ®Google Scholar
• Delage G. Rotavirus vaccine withdrawal in the United states; the role of postmarketing surveillance. Can J Infect Dis. 2000;11(1):10–12. doi:10.1155/2000/414396.
   PubMedGoogle Scholar
• European Medicines Agency. Rotarix® Summary of product characteristics, 11/ 05/2017update. [ accessed November, 2020]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000639/WC500054789.pdf
   Google Scholar
• European Medicines Agency. RotaTeq summary of product characteristics, 30/ 05/2017update. [ accessed November, 2020]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000669/WC500054185.pdf
   Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354(1):11–22. doi:10.1056/NEJMoa052434.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354(1):23–33. doi:10.1056/NEJMoa052664.
   PubMed Web of Science ®Google Scholar
• International Vaccine Access Center (IVAC) JHBSoPH. VIEW-hub RV- Vaccine introduction: current dosing schedule. 2020.[ accessed December, 2019]. https://view-hub.org/map/?set=current-dosing-schedule&group=vaccine-introduction&category=rv
   Google Scholar
• Centers for Disease Control and Prevention. Vaccines and preventable diseases: routine vaccine recommendations. [ accessed November, 2020]. https://www.cdc.gov/vaccines/vpd/rotavirus/hcp/recommendations.html
   Google Scholar
• Kirkwood CD, Ma LF, Carey ME, Steele AD. The rotavirus vaccine development pipeline. Vaccine. 2019;37(50):7328–35. doi:10.1016/j.vaccine.2017.03.076.
   PubMed Web of Science ®Google Scholar
• Burke RM, Tate JE, Kirkwood CD, Steele AD, Parashar UD. Current and new rotavirus vaccines. Curr Opin Infect Dis. 2019;32(5):435–44. doi:10.1097/QCO.0000000000000572.
   PubMed Web of Science ®Google Scholar
• De Vos B, Han HH, Bouckenooghe A, Debrus S, Gillard P, Ward R. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. Pediatr Infect Dis J. 2009;28(4):261–66. doi:10.1097/INF.0b013e3181907177.
   PubMed Web of Science ®Google Scholar
• Leshem E, Lopman B, Glass R, Gentsch J, Banyai K, Parashar U. Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(9):847–56. doi:10.1016/s1473-3099(14)70832-1.
   PubMed Web of Science ®Google Scholar
• Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9935):2136–43. doi:10.1016/S0140-6736(13)62630-6.
   PubMed Web of Science ®Google Scholar
• Dang DA, Nguyen VT, Vu DT, Nguyen TH, Nguyen DM, Yuhuan W. A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children. Vaccine. 2012;30(Suppl 1):A114–121. doi:10.1016/j.vaccine.2011.07.118.
   PubMed Web of Science ®Google Scholar
• Bhandari N, Rongsen-Chandola T, Bavdekar A, John J, Antony K, Taneja S. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in indian children in the second year of life. Vaccine. 2014;32(Suppl 1):A110–116. doi:10.1016/j.vaccine.2014.04.079.
   PubMed Web of Science ®Google Scholar
• Bines JE, Danchin M, Jackson P, Handley A, Watts E, Lee KJ. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2015;15(12):1389–97. doi:10.1016/s1473-3099(15)00227-3.
   PubMed Web of Science ®Google Scholar
• Deen J, Lopez AL, Kanungo S, Wang XY, Anh DD, Tapia M. Improving rotavirus vaccine coverage: can newer-generation and locally produced vaccines help? Hum Vaccin Immunother. 2018;14(2):495–99. doi:10.1080/21645515.2017.1403705.
   PubMed Web of Science ®Google Scholar
• Chandola TR, Taneja S, Goyal N, Antony K, Bhatia K, More D. ROTAVAC® does not interfere with the immune response to childhood vaccines in indian infants: A randomized placebo controlled trial. Heliyon. 2017;3(5):e00302–e00302. doi:10.1016/j.heliyon.2017.e00302.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO prequalified vaccines. [ accessed November, 2020]. https://extranet.who.int/gavi/PQ_Web/Browse.aspx?nav=3
   Google Scholar
• Velazquez RF, Linhares AC, Munoz S, Seron P, Lorca P, DeAntonio R. Efficacy, safety and effectiveness of licensed rotavirus vaccines: a systematic review and meta-analysis for Latin America and the Caribbean. BMC Pediatr. 2017;17(1):14. doi:10.1186/s12887-016-0771-y.
   PubMed Web of Science ®Google Scholar
• Bines JE, At Thobari J, Satria CD, Handley A, Watts E, Cowley D. Human neonatal rotavirus vaccine (RV3-BB) to target rotavirus from Birth. N Engl J Med. 2018;378(8):719–30. doi:10.1056/NEJMoa1706804.
   PubMed Web of Science ®Google Scholar
• Willame C, Vonk Noordegraaf-Schouten M, Gvozdenovic E, Kochems K, Oordt-Speets A, Praet N. Effectiveness of the oral human attenuated rotavirus vaccine: A systematic review and meta-analysis-2006-2016. Open Forum Infect Dis. 2018;5(11):ofy292. doi:10.1093/ofid/ofy292.
   PubMed Web of Science ®Google Scholar
• Jonesteller CL, Burnett E, Yen C, Tate JE, Parashar UD. Effectiveness of rotavirus vaccination: A systematic review of the first decade of global postlicensure data, 2006-2016. Clin Infect Dis. 2017;65(5):840–50. doi:10.1093/cid/cix369.
   PubMed Web of Science ®Google Scholar
• Reddy S, Nair NP, Giri S, Mohan VR, Tate JE, Parashar UD. Safety monitoring of ROTAVAC vaccine and etiological investigation of intussusception in India: study protocol. BMC Public Health. 2018;18(1):898. doi:10.1186/s12889-018-5809-7.
   PubMedGoogle Scholar
• Fu C, He Q, Xu J, Xie H, Ding P, Hu W. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. Vaccine. 2012;31(1):154–58. doi:10.1016/j.vaccine.2012.10.078.
   PubMed Web of Science ®Google Scholar
• Fu C, Wang M, Liang J, He T, Wang D, Xu J. Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a matched case-control study. Vaccine. 2007;25(52):8756–61. doi:10.1016/j.vaccine.2007.10.036.
   PubMed Web of Science ®Google Scholar
• Fu C, Tate JE, Jiang B. Effectiveness of Lanzhou lamb rotavirus vaccine against hospitalized gastroenteritis: further analysis and update. Hum Vaccin. 2010;6(11):953. doi:10.4161/hv.6.11.12847.
   PubMed Web of Science ®Google Scholar
• Zhen SS, Li Y, Wang SM, Zhang XJ, Hao ZY, Chen Y. Effectiveness of the live attenuated rotavirus vaccine produced by a domestic manufacturer in China studied using a population-based case-control design. Emerg Microbes Infect. 2015;4(1):e64. doi:10.1038/emi.2015.64.
   PubMedGoogle Scholar
• Isanaka S, Guindo O, Langendorf C, Matar Seck A, Plikaytis BD, Sayinzoga-Makombe N. Efficacy of a low-cost, heat-stable oral rotavirus vaccine in Niger. N Engl J Med. 2017;376(12):1121–30. doi:10.1056/NEJMoa1609462.
   PubMed Web of Science ®Google Scholar
• Zade JK, Kulkarni PS, Desai SA, Sabale RN, Naik SP, Dhere RM. Bovine rotavirus pentavalent vaccine development in India. Vaccine. 2014;32(Suppl 1):A124–128. doi:10.1016/j.vaccine.2014.03.003.
   PubMed Web of Science ®Google Scholar
• Kapikian AZ, Simonsen L, Vesikari T, Hoshino Y, Morens DM, Chanock RM. A hexavalent human rotavirus-bovine rotavirus (UK) reassortant vaccine designed for use in developing countries and delivered in a schedule with the potential to eliminate the risk of intussusception. J Infect Dis. 2005;192(Suppl 1):S22–29. doi:10.1086/431510.
   PubMed Web of Science ®Google Scholar
• Luna EJ, Frazatti-Gallina NM, Timenetsky MC, Cardoso MR, Veras MA, Miraglia JL. A phase I clinical trial of a new 5-valent rotavirus vaccine. Vaccine. 2013;31(7):1100–05. doi:10.1016/j.vaccine.2012.12.020.
   PubMed Web of Science ®Google Scholar
• Kulkarni PS, Desai S, Tewari T, Kawade A, Goyal N, Garg BS. A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants. Vaccine. 2017;35(45):6228–37. doi:10.1016/j.vaccine.2017.09.014.
   PubMed Web of Science ®Google Scholar
• Skansberg A, Sauer M, Tan M, Santosham M, Jennings MC. Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1. Hum Vaccin Immunother. 2020:1–12. doi:10.1080/21645515.2020.1804245.
   PubMedGoogle Scholar
• Armah GE, Sow SO, Breiman RF, Dallas MJ, Tapia MD, Feikin DR. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):606–14. doi:10.1016/s0140-6736(10)60889-6.
   PubMed Web of Science ®Google Scholar
• Breiman RF, Zaman K, Armah G, Sow SO, Anh DD, Victor JC. Analyses of health outcomes from the 5 sites participating in the Africa and Asia clinical efficacy trials of the oral pentavalent rotavirus vaccine. Vaccine. 2012;30(Suppl 1):A24–29. doi:10.1016/j.vaccine.2011.08.124.
   PubMed Web of Science ®Google Scholar
• Zaman K, Dang DA, Victor JC, Shin S, Yunus M, Dallas MJ. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;376(9741):615–23. doi:10.1016/s0140-6736(10)60755-6.
   PubMed Web of Science ®Google Scholar
• Block SL, Vesikari T, Goveia MG, Rivers SB, Adeyi BA, Dallas MJ. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics. 2007;119(1):11–18. doi:10.1542/peds.2006-2058.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Itzler R, Matson DO, Santosham M, Christie CD, Coia M. Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries). Int J Infect Dis. 2007;11(Suppl 2):S29–35. doi:10.1016/s1201-9712(07)60019-8.
   PubMedGoogle Scholar
• Dhingra MS, Kundu R, Gupta M, Kanungo S, Ganguly N, Singh MP. Evaluation of safety and immunogenicity of a live attenuated tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus vaccine (BRV-TV) in healthy Indian adults and infants. Vaccine. 2014;32(Suppl 1):A117–123. doi:10.1016/j.vaccine.2014.03.069.
   PubMed Web of Science ®Google Scholar
• Saluja T, Palkar S, Misra P, Gupta M, Venugopal P, Sood AK. Live attenuated tetravalent (G1-G4) bovine-human reassortant rotavirus vaccine (BRV-TV): randomized, controlled phase III study in Indian infants. Vaccine. 2017;35(28):3575–81. doi:10.1016/j.vaccine.2017.05.019.
   PubMed Web of Science ®Google Scholar
• Belongia EA, Irving SA, Shui IM, Kulldorff M, Lewis E, Yin R. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J. 2010;29(1):1–5. doi:10.1097/INF.0b013e3181af8605.
   PubMed Web of Science ®Google Scholar
• Jiang B, Wang Y, Glass RI. Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? evidence from animal studies. Hum Vaccin Immunother. 2013;9(8):1634–37. doi:10.4161/hv.24958.
   PubMed Web of Science ®Google Scholar
• Wang Y, Azevedo M, Saif LJ, Gentsch JR, Glass RI, Jiang B. Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine. 2010;28(33):5432–36. doi:10.1016/j.vaccine.2010.06.006.
   PubMed Web of Science ®Google Scholar
• Fix AD, Harro C, McNeal M, Dally L, Flores J, Robertson G. Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults. Vaccine. 2015;33(31):3766–72. doi:10.1016/j.vaccine.2015.05.024.
   PubMed Web of Science ®Google Scholar
• Groome MJ, Koen A, Fix A, Page N, Jose L, Madhi SA. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2017;17(8):843–53. doi:10.1016/s1473-3099(17)30242-6.
   PubMed Web of Science ®Google Scholar
• Resch TK, Wang Y, Moon -S-S, Joyce J, Li S, Prausnitz M. Inactivated rotavirus vaccine by parenteral administration induces mucosal immunity in mice. Sci Rep. 2018;8(1):561. doi:10.1038/s41598-017-18973-9.
   PubMedGoogle Scholar
• Wang Y, Vlasova A, Velasquez DE, Saif LJ, Kandasamy S, Kochba E. Skin vaccination against rotavirus using microneedles: proof of concept in gnotobiotic piglets. Plos One. 2016;11(11):e0166038. doi:10.1371/journal.pone.0166038.
   PubMed Web of Science ®Google Scholar
• Ward RL, McNeal MM. VP6: A candidate rotavirus vaccine. J Infect Dis. 2010;202(S1):S101–107. doi:10.1086/653556.
   PubMedGoogle Scholar
• Esteban LE, Temprana CF, Arguelles MH, Glikmann G, Castello AA. Antigenicity and immunogenicity of rotavirus VP6 protein expressed on the surface of Lactococcus lactis. Biomed Res Int. 2013;2013:298598. doi:10.1155/2013/298598.
   PubMed Web of Science ®Google Scholar
• Temprana CF, Arguelles MH, Gutierrez NM, Barril PA, Esteban LE, Silvestre D. Rotavirus VP6 protein mucosally delivered by cell wall-derived particles from Lactococcus lactis induces protection against infection in a murine model. PLoS One. 2018;13(9):e0203700. doi:10.1371/journal.pone.0203700.
   PubMed Web of Science ®Google Scholar
• Changotra H, Vij A. Rotavirus virus-like particles (RV-VLPs) vaccines: an update. Rev Med Virol. 2017;(6)27. doi:10.1002/rmv.1954.
   Google Scholar
• Conner ME, Zarley CD, Hu B, Parsons S, Drabinski D, Greiner S. Virus-like particles as a rotavirus subunit vaccine. J Infect Dis. 1996;174(Suppl 1):S88–92. doi:10.1093/infdis/174.supplement_1.s88.
   PubMedGoogle Scholar
• Lappalainen S, Pastor AR, Malm M, Lopez-Guerrero V, Esquivel-Guadarrama F, Palomares LA. Protection against live rotavirus challenge in mice induced by parenteral and mucosal delivery of VP6 subunit rotavirus vaccine. Arch Virol. 2015;160(8):2075–78. doi:10.1007/s00705-015-2461-8.
   PubMed Web of Science ®Google Scholar
• Lappalainen S, Pastor AR, Tamminen K, Lopez-Guerrero V, Esquivel-Guadarrama F, Palomares LA. Immune responses elicited against rotavirus middle layer protein VP6 inhibit viral replication in vitro and in vivo. Hum Vaccin Immunother. 2014;10(7):2039–47. doi:10.4161/hv.28858.
   PubMed Web of Science ®Google Scholar
• Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One. 2013;8(7):e70409. doi:10.1371/journal.pone.0070409.
   PubMed Web of Science ®Google Scholar
• Azevedo MS, Gonzalez AM, Yuan L, Jeong KI, Iosef C, Van Nguyen T. An oral versus intranasal prime/boost regimen using attenuated human rotavirus or VP2 and VP6 virus-like particles with immunostimulating complexes influences protection and antibody-secreting cell responses to rotavirus in a neonatal gnotobiotic pig model. Clin Vaccine Immunol. 2010;17(3):420–28. doi:10.1128/CVI.00395-09.
   PubMed Web of Science ®Google Scholar
• Banyai K, Laszlo B, Duque J, Steele AD, Nelson EA, Gentsch JR. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine. 2012;30(Suppl 1):A122–130. doi:10.1016/j.vaccine.2011.09.111.
   PubMedGoogle Scholar
• Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Rev Med Virol. 2005;15(1):29–56. doi:10.1002/rmv.448.
   PubMed Web of Science ®Google Scholar
• Matthijnssens J, Nakagomi O, Kirkwood CD, Ciarlet M, Desselberger U, Van Ranst M. Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes? Expert Rev Vaccines. 2012;11(11):1347–54. doi:10.1586/erv.12.105.
   PubMed Web of Science ®Google Scholar
• Kirkwood CD. Genetic and antigenic diversity of human rotaviruses: potential impact on vaccination programs. J Infect Dis. 2010;202(S1):S43–48. doi:10.1086/653548.
   PubMed Web of Science ®Google Scholar
• EuroRotaNet Annual Report 2018. Publication of report dated Sept 2019. [ accessed November, 2020]. http://www.eurorotanet.com/wp-content/uploads/2019/09/EuroRotaNet_report-Sept_2019_v1.pdf
   Google Scholar
• Carvalho-Costa FA, Assis RMS de, Fialho AM, Araujo IT, Silva MF, Gomez MM. The evolving epidemiology of rotavirus A infection in Brazil a decade after the introduction of universal vaccination with Rotarix(R). BMC Pediatr. 2019;19(1):42. doi:10.1186/s12887-019-1415-9.
   PubMed Web of Science ®Google Scholar
• Roczo-Farkas S, Cowley D, Bines JE. Australian rotavirus surveillance program: annual report, 2017. Commun Dis Intell. 2018;2019:43. doi:10.33321/cdi.2019.43.28.
   Google Scholar
• Doro R, Laszlo B, Martella V, Leshem E, Gentsch J, Parashar U. Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: is there evidence of strain selection from vaccine pressure? Infect Genet Evol. 2014;28:446–61. doi:10.1016/j.meegid.2014.08.017.
   PubMed Web of Science ®Google Scholar
• Usonis V, Ivaskeviciene I, Desselberger U, Rodrigo C. The unpredictable diversity of co-circulating rotavirus types in Europe and the possible impact of universal mass vaccination programmes on rotavirus genotype incidence. Vaccine. 2012;30(31):4596–605. doi:10.1016/j.vaccine.2012.04.097.
   PubMed Web of Science ®Google Scholar
• Bhandari N, Sharma P, Glass RI, Ray P, Greenberg H, Taneja S. Safety and immunogenicity of two live attenuated human rotavirus vaccine candidates, 116E and I321, in infants: results of a randomised controlled trial. Vaccine. 2006;24(31–32):5817–23. doi:10.1016/j.vaccine.2006.05.001.
   PubMed Web of Science ®Google Scholar
• Bishop RF, Barnes GL, Cipriani E, Lund JS. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med. 1983;309(2):72–76. doi:10.1056/NEJM198307143090203.
   PubMed Web of Science ®Google Scholar
• Danchin M, Kirkwood CD, Lee KJ, Bishop RF, Watts E, Justice FA. Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine. Vaccine. 2013;31(23):2610–16. doi:10.1016/j.vaccine.2013.04.008.
   PubMed Web of Science ®Google Scholar
• A phase II dose-ranging study of oral RV3-BB rotavirus vaccine. [ accessed November, 2020]. https://clinicaltrials.gov/ct2/show/NCT03483116
   Google Scholar
• Soares-Weiser K, Bergman H, Henschke N, Pitan F, Cunliffe N. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2019:2019. doi:10.1002/14651858.CD008521.pub5.
   Google Scholar
• Pereira P, Vetter V, Standaert B, Benninghoff B. Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned. Expert Rev Vaccines. 2020;19(8):755–69. doi:10.1080/14760584.2020.1800459.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Phase III study of liquid formulation of ROTAVIN. 2018.[ accessed November, 2020]. https://clinicaltrials.gov/ct2/show/NCT03703336
   Google Scholar
• Li D, Xu Z, Xie G, Wang H, Zhang Q, Sun X. [Genotype of rotavirus vaccine strain LLR in China is G10P[15]]. Bing Du Xue Bao. 2015;31(2):170–73. doi:10.1001/jamanetworkopen.2018.1382.
   PubMedGoogle Scholar
• Fu C, Dong Z, Shen J, Yang Z, Liao Y, Hu W. Rotavirus gastroenteritis infection among children vaccinated and unvaccinated with rotavirus vaccine in Southern China: A population-based assessment. JAMA Netw Open. 2018;1(4):e181382. doi:10.1001/jamanetworkopen.2018.1382.
   PubMed Web of Science ®Google Scholar
• Desselberger U. Differences of rotavirus vaccine effectiveness by Country: likely causes and contributing factors. Pathogens. 2017;6(4):65. doi:10.3390/pathogens6040065.
   PubMed Web of Science ®Google Scholar
• Desai S, Rathi N, Kawade A, Venkatramanan P, Kundu R, Lalwani SK. Non-interference of bovine-human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine. Vaccine. 2018;36(37):5519–23. doi:10.1016/j.vaccine.2018.07.064.
   PubMed Web of Science ®Google Scholar
• Kawade A, Babji S, Kamath V, Raut A, Kumar CM, Kundu R. Immunogenicity and lot-to-lot consistency of a ready to use liquid bovine-human reassortant pentavalent rotavirus vaccine (ROTASIIL - Liquid) in Indian infants. Vaccine. 2019;37(19):2554–60. doi:10.1016/j.vaccine.2019.03.067.
   PubMed Web of Science ®Google Scholar
• Burnett E, Parashar U, Tate J. Rotavirus vaccines: effectiveness, safety, and future directions. Paediatr Drugs. 2018;20(3):223–33. doi:10.1007/s40272-018-0283-3.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zade J, Moon SS, Weldon W, Pisal SS, Glass RI. Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species. Vaccine. 2019;37(5):698–704. doi:10.1016/j.vaccine.2018.12.043.
   PubMed Web of Science ®Google Scholar
• Groome MJ, Fairlie L, Morrison J, Fix A, Koen A, Masenya M. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2020;(7). doi:10.1016/s1473-3099(20)30001-3.
   PubMedGoogle Scholar
• Safety, immunogenicity and efficacy of a trivalent rotavirus P2-VP8 subunit vaccine in prevention of severe rotavirus gastroenteritis in healthy infants in Africa and India. [ accessed November, 2020]. https://www.clinicaltrials.gov/ct2/show/NCT04010448
   Google Scholar
• Vesikari T, Karvonen A, Korhonen T, Espo M, Lebacq E, Forster J. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine. 2004;22(21–22):2836–42. doi:10.1016/j.vaccine.2004.01.044.
   PubMed Web of Science ®Google Scholar
• Cunliffe N, Zaman K, Rodrigo C, Debrus S, Benninghoff B, Pemmaraju Venkata S. Early exposure of infants to natural rotavirus infection: a review of studies with human rotavirus vaccine RIX4414. BMC Pediatr. 2014;14(1):295. doi:10.1186/s12887-014-0295-2.
   PubMed Web of Science ®Google Scholar
• Koch J, Harder T, von Kries R, Wichmann O. Risk of intussusception after rotavirus vaccination. Dtsch Arztebl Int. 2017;114(15):255–62. doi:10.3238/arztebl.2017.0255.
   PubMed Web of Science ®Google Scholar
• Valcarcel Salamanca B, Hagerup-Jenssen ME, Flem E. Uptake and timeliness of rotavirus vaccination in Norway: the first year post-introduction. Vaccine. 2016;34(39):4684–89. doi:10.1016/j.vaccine.2016.08.017.
   PubMed Web of Science ®Google Scholar
• Patel MM, Clark AD, Glass RI, Greenberg H, Tate J, Santosham M. Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception. Vaccine. 2009;27(22):2916–22. doi:10.1016/j.vaccine.2009.03.016.
   PubMed Web of Science ®Google Scholar
• Patel MM, Clark AD, Sanderson CF, Tate J, Parashar UD. Removing the age restrictions for rotavirus vaccination: a benefit-risk modeling analysis. PLoS Med. 2012;9(10):e1001330. doi:10.1371/journal.pmed.1001330.
   PubMed Web of Science ®Google Scholar
• Dudareva-Vizule S, Koch J, An der Heiden M, Oberle D, Keller-Stanislawski B, Wichmann O. Impact of rotavirus vaccination in regions with low and moderate vaccine uptake in Germany. Hum Vaccin Immunother. 2012;8(10):1407–15. doi:10.4161/hv.21593.
   PubMed Web of Science ®Google Scholar
• Steele AD, Groome MJ. Measuring rotavirus vaccine impact in Sub-Saharan Africa. Clin Infect Dis. 2020;70(11):2314–16. doi:10.1093/cid/ciz918.
   PubMed Web of Science ®Google Scholar
• Luna-Casas G, Juliao P, Carreno-Manjarrez R, Castaneda-Prado A, Cervantes-Apolinar MY, Navarro-Rodriguez R. Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines. Hum Vaccin Immunother. 2019;15(6):1251–59. doi:10.1080/21645515.2018.1540827.
   PubMed Web of Science ®Google Scholar
• Krishnarajah G, Landsman-Blumberg P, Eynullayeva E. Rotavirus vaccination compliance and completion in a Medicaid infant population. Vaccine. 2015;33(3):479–86. doi:10.1016/j.vaccine.2014.06.059.
   PubMed Web of Science ®Google Scholar
• Cheuvart B, Neuzil KM, Steele AD, Cunliffe N, Madhi SA, Karkada N. Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: analysis of clinical trials of human rotavirus vaccine. Hum Vaccin Immunother. 2014;10(2):505–11. doi:10.4161/hv.27097.
   PubMed Web of Science ®Google Scholar
• Angel J, Steele AD, Franco MA. Correlates of protection for rotavirus vaccines: possible alternative trial endpoints, opportunities, and challenges. Hum Vaccin Immunother. 2014;10(12):3659–71. doi:10.4161/hv.34361.
   PubMed Web of Science ®Google Scholar
• Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis. 2013;208(2):284–94. doi:10.1093/infdis/jit166.
   PubMed Web of Science ®Google Scholar
• Baker JM, Tate JE, Leon J, Haber MJ, Pitzer VE, Lopman BA. Postvaccination serum antirotavirus immunoglobulin A as a correlate of protection against rotavirus gastroenteritis across settings. J Infect Dis. 2020;222(2):309–18. doi:10.1093/infdis/jiaa068.
   PubMed Web of Science ®Google Scholar
• Pindyck T, Tate JE, Parashar UD. A decade of experience with rotavirus vaccination in the United States - vaccine uptake, effectiveness, and impact. Expert Rev Vaccines. 2018;17(7):593–606. doi:10.1080/14760584.2018.1489724.
   PubMed Web of Science ®Google Scholar
• Goveia MG, Rodriguez ZM, Dallas MJ, Itzler RF, Boslego JW, Heaton PM. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J. 2007;26(12):1099–104. doi:10.1097/INF.0b013e31814521cb.
   PubMed Web of Science ®Google Scholar
• Van der Wielen M, Van Damme P. Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the rotavirus efficacy and safety trial. Eur J Clin Microbiol Infect Dis. 2008;27(7):495–501. doi:10.1007/s10096-008-0479-5.
   PubMed Web of Science ®Google Scholar
• J-M R, Nowak E, Le Gal G, Lemaitre T, Oger E, Poulhazan E. Impact of rotavirus vaccine on premature infants. Clinical and Vaccine Immunology: CVI. 2014;21(10):1404–09. doi:10.1128/CVI.00265-14.
   PubMedGoogle Scholar
• Groome MJ, Zell ER, Solomon F, Nzenze S, Parashar UD, Izu A. Temporal association of rotavirus vaccine introduction and reduction in all-cause childhood diarrheal hospitalizations in South Africa. Clin Infect Dis. 2016;62(Suppl 2):S188–195. doi:10.1093/cid/civ1204.
   PubMedGoogle Scholar
• Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C. Effect of human rotavirus vaccine on severe diarrhea in African infants. Malawi Med J. 2016;28(3):108–14. doi:10.1093/cid/civ1204.
   PubMed Web of Science ®Google Scholar
• Perez-Schael I, Salinas B, Tomat M, Linhares AC, Guerrero ML, Ruiz-Palacios GM. Efficacy of the human rotavirus vaccine RIX4414 in malnourished children. J Infect Dis. 2007;196(4):537–40. doi:10.1086/519687.
   PubMed Web of Science ®Google Scholar
• Esposito S, Pugni L, Mosca F, Principi N. Rotarix® and RotaTeq® administration to preterm infants in the neonatal intensive care unit: review of available evidence. Vaccine. 2018;36(36):5430–34. doi:10.1016/j.vaccine.2017.10.013.
   PubMed Web of Science ®Google Scholar
• Patel M, Shane AL, Parashar UD, Jiang B, Gentsch JR, Glass RI. Oral rotavirus vaccines: how well will they work where they are needed most? J Infect Dis. 2009;200(Suppl s1):S39–48. doi:10.1086/605035.
   PubMedGoogle Scholar
• Field EJ, Vally H, Grimwood K, Lambert SB. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics. 2010;126(3):e506–512. doi:10.1542/peds.2010-0443.
   PubMed Web of Science ®Google Scholar
• Safadi MA, Berezin EN, Munford V, Almeida FJ, de Moraes JC, Pinheiro CF. Hospital-based surveillance to evaluate the impact of rotavirus vaccination in Sao Paulo, Brazil. Pediatr Infect Dis J. 2010;29(11):1019–22. doi:10.1097/INF.0b013e3181e7886a.
   PubMed Web of Science ®Google Scholar
• Hemming M, Rasanen S, Huhti L, Paloniemi M, Salminen M, Vesikari T. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the national immunization programme in Finland. Eur J Pediatr. 2013;172(6):739–46. doi:10.1007/s00431-013-1945-3.
   PubMed Web of Science ®Google Scholar
• Paulke-Korinek M, Kundi M, Rendi-Wagner P, de Martin A, Eder G, Schmidle-Loss B. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine. 2011;29(15):2791–96. doi:10.1016/j.vaccine.2011.01.104.
   PubMed Web of Science ®Google Scholar
• Raes M, Strens D, Vergison A, Verghote M, Standaert B. Reduction in pediatric rotavirus-related hospitalizations after universal rotavirus vaccination in Belgium. Pediatr Infect Dis J. 2011;30(7):e120–125. doi:10.1097/INF.0b013e318214b811.
   PubMed Web of Science ®Google Scholar
• Yen C, Armero Guardado JA, Alberto P, Rodriguez Araujo DS, Mena C, Cuellar E. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J. 2011;30:S6–S10. doi:10.1097/INF.0b013e3181fefa05.
   PubMed Web of Science ®Google Scholar
• Standaert B, Strens D, Alwan A, Raes M. Medium- to long-term impact of rotavirus vaccination on hospital care in Belgium: A 7-year follow-up of the Rotavirus Belgium Impact Study (RotaBIS). Infect Dis Ther. 2016;5(1):31–44. doi:10.1007/s40121-015-0099-1.
   PubMed Web of Science ®Google Scholar
• Standaert B, Strens D, Li X, Schecroun N, Raes M. The sustained rotavirus vaccination impact on nosocomial infection, duration of hospital stay, and age: the rotaBIS study (2005-2012). Infect Dis Ther. 2016;5(4):509–24. doi:10.1007/s40121-016-0131-0.
   PubMed Web of Science ®Google Scholar
• Zlamy M, Kofler S, Orth D, Wurzner R, Heinz-Erian P, Streng A. The impact of rotavirus mass vaccination on hospitalization rates, nosocomial rotavirus gastroenteritis and secondary blood stream infections. BMC Infect Dis. 2013;13(1):112. doi:10.1186/1471-2334-13-112.
   PubMedGoogle Scholar
• Burke RM, Tate JE, Dahl RM, Aliabadi N, Parashar UD. Rotavirus vaccination is associated with reduced seizure hospitalization risk among commercially insured US children. Clin Infect Dis. 2018;67(10):1614–16. doi:10.1093/cid/ciy424.
   PubMed Web of Science ®Google Scholar
• Hemming-Harlo M, Lahdeaho ML, Maki M, Vesikari T. Rotavirus vaccination does not increase Type 1 diabetes and may decrease celiac disease in children and adolescents. Pediatr Infect Dis J. 2019;38(5):539–41. doi:10.1097/INF.0000000000002281.
   PubMed Web of Science ®Google Scholar
• Burke RM, Tate JE, Jiang B, Parashar UD. Rotavirus and Type 1 diabetes-is there a connection? A synthesis of the evidence. J Infect Dis. 2020;222(7):1076–83. doi:10.1093/infdis/jiaa168.
   PubMed Web of Science ®Google Scholar
• Pecenka C, Debellut F, Bar-Zeev N, Anwari P, Nonvignon J, Shamsuzzaman M. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines. Vaccine. 2018;36(49):7472–78. doi:10.1016/j.vaccine.2018.10.068.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines to assure the quality, safety and efficacy of live attenuated rotavirus vaccine. 2007.[ accessed November, 2017]. http://www.who.int/biologicals/publications/trs/areas/vaccines/rotavirus/Annex%203%20rotavirus%20vaccines.pdf
   Google Scholar
• Lopalco PL, DeStefano F. The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines. Vaccine. 2015;33(13):1541–48. doi:10.1016/j.vaccine.2014.10.047.
   PubMed Web of Science ®Google Scholar
• Jiang J, Jiang B, Parashar U, Nguyen T, Bines J, Patel MM. Childhood intussusception: a literature review. PLoS One. 2013;8(7):e68482. doi:10.1371/journal.pone.0068482.
   PubMed Web of Science ®Google Scholar
• Clark AD, Hasso-Agopsowicz M, Kraus MW, Stockdale LK, Sanderson CFB, Parashar UD. Update on the global epidemiology of intussusception: a systematic review of incidence rates, age distributions and case-fatality ratios among children aged <5 years, before the introduction of rotavirus vaccination. Int J Epidemiol. 2019;48(4):1316–26. doi:10.1093/ije/dyz028.
   PubMed Web of Science ®Google Scholar
• Cheuvart B, Friedland LR, Abu-Elyazeed R, Han HH, Guerra Y, Verstraeten T. The human rotavirus vaccine RIX4414 in infants: a review of safety and tolerability. Pediatr Infect Dis J. 2009;28(3):225–32. doi:10.1097/INF.0b013e31819715fa.
   PubMed Web of Science ®Google Scholar
• Dong R, Yang Y-F, Chen G, Shen Z, Zheng S. Risk of intussusception after rotavirus vaccination: a meta-analysis. Int J Clin Exp Med. 2016;9:1306–13. doi:10.1097/INF.0b013e31819715fa.
   Web of Science ®Google Scholar
• Rosillon D, Buyse H, Friedland LR, Ng SP, Velazquez FR, Breuer T. Risk of intussusception after rotavirus vaccination: meta-analysis of postlicensure studies. Pediatr Infect Dis J. 2015;34(7):763–68. doi:10.1097/INF.0000000000000715.
   PubMed Web of Science ®Google Scholar
• Kassim P, Eslick GD. Risk of intussusception following rotavirus vaccination: an evidence based meta-analysis of cohort and case-control studies. Vaccine. 2017;35(33):4276–86. doi:10.1016/j.vaccine.2017.05.064.
   PubMed Web of Science ®Google Scholar
• Organization WH. Global advisory committee on vaccine safety, 6-7 December 2017. Wkly Epidemiol Rec. 2018;93(3):17–32.
   PubMedGoogle Scholar
• Organization WH. Global advisory committee on vaccine safety, 4-5 December 2019. Wkly Epidemiol Rec. 2020;95(4):25–36.
   Google Scholar
• Burke RM, Tate JE, Dahl RM, Aliabadi N, Parashar UD. Does rotavirus vaccination affect longer-term intussusception risk in US infants? J Pediatric Infect Dis Soc. 2019. doi:10.1093/jpids/piz035.
   PubMed Web of Science ®Google Scholar
• Buttery JP, Danchin MH, Lee KJ, Carlin JB, McIntyre PB, Elliott EJ. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the national immunization program in Australia. Vaccine. 2011;29(16):3061–66. doi:10.1016/j.vaccine.2011.01.088.
   PubMed Web of Science ®Google Scholar
• Hawken S, Ducharme R, Rosella LC, Benchimol EI, Langley JM, Wilson K. Assessing the risk of intussusception and rotavirus vaccine safety in Canada. Hum Vaccin Immunother. 2017;13(3):703–10. doi:10.1080/21645515.2016.1240846.
   PubMed Web of Science ®Google Scholar
• Yen C, Tate JE, Steiner CA, Cortese MM, Patel MM, Parashar UD. Trends in intussusception hospitalizations among US infants before and after implementation of the rotavirus vaccination program, 2000-2009. J Infect Dis. 2012;206(1):41–48. doi:10.1093/infdis/jis314.
   PubMed Web of Science ®Google Scholar
• Cho H-K, Hwang SH, Nam HN, Han K, Kim B, Kong I. Incidence of intussusception before and after the introduction of rotavirus vaccine in Korea. PloS One. 2020;15(8):e0238185–e0238185. doi:10.1371/journal.pone.0238185.
   PubMed Web of Science ®Google Scholar
• Yen C, Shih SM, Tate JE, Wu FT, Huang YC, Parashar UD. Intussusception-related hospitalizations among infants before and after private market licensure of rotavirus vaccines in Taiwan, 2001-2013. Pediatr Infect Dis J. 2017;36(10):e252–e257. doi:10.1097/INF.0000000000001644.
   PubMed Web of Science ®Google Scholar
• John J, Kawade A, Rongsen-Chandola T, Bavdekar A, Bhandari N, Taneja S. Active surveillance for intussusception in a phase III efficacy trial of an oral monovalent rotavirus vaccine in India. Vaccine. 2014;32(Suppl 1):A104–109. doi:10.1016/j.vaccine.2014.03.036.
   PubMed Web of Science ®Google Scholar
• Escolano S, Hill C, Tubert-Bitter P. A new self-controlled case series method for analyzing spontaneous reports of adverse events after vaccination. Am J Epidemiol. 2013;178(9):1496–504. doi:10.1093/aje/kwt128.
   PubMed Web of Science ®Google Scholar
• Hofstetter AM, Lacombe K, Klein EJ, Jones C, Strelitz B, Jacobson E. Risk of rotavirus nosocomial spread after inpatient pentavalent rotavirus vaccination. Pediatrics. 2018;(1)141. doi:10.1542/peds.2017-1110.
   Google Scholar
• Pahud B, Pallotto EK. Rotavirus Immunization for hospitalized infants: are we there yet? Pediatrics. 2018;(1)141. doi:10.1542/peds.2017-3499.
   Google Scholar
• Kilich E, Sadarangani M. Use of rotavirus vaccines in preterm babies on the neonatal unit. Expert Rev Vaccines. 2016;15(12):1463–65. doi:10.1080/14760584.2016.1216318.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. 2007. [ accessed November, 2020]. http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf
   Google Scholar
• Steele AD, Madhi SA, Louw CE, Bos P, Tumbo JM, Werner CM. Safety, reactogenicity, and immunogenicity of human rotavirus vaccine RIX4414 in human immunodeficiency virus-positive infants in South Africa. Pediatr Infect Dis J. 2011;30(2):125–30. doi:10.1097/INF.0b013e3181f42db9.
   PubMed Web of Science ®Google Scholar
• Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P. Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine. 2010;28(39):6542–48. doi:10.1016/j.vaccine.2008.08.034.
   PubMed Web of Science ®Google Scholar
• Levin MJ, Lindsey JC, Kaplan SS, Schimana W, Lawrence J, McNeal MM. Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS. 2017;31(1):49–59. doi:10.1097/qad.0000000000001258.
   PubMed Web of Science ®Google Scholar
• McGrath EJ, Thomas R, Duggan C, Asmar BI. Pentavalent rotavirus vaccine in infants with surgical gastrointestinal disease. J Pediatr Gastroenterol Nutr. 2014;59(1):44–48. doi:10.1097/MPG.0000000000000361.
   PubMed Web of Science ®Google Scholar
• Javid PJ, Sanchez SE, Jacob S, McNeal MM, Horslen SP, Englund JA. The Safety and Immunogenicity of rotavirus vaccination in infants with intestinal failure. J Pediatric Infect Dis Soc. 2014;3(1):57–65. doi:10.1093/jpids/pit060.
   PubMedGoogle Scholar